Cardiovascular Research

Sexual function in hypertensive patients receiving treatment.

Authors: Thorsten Reffelmann|||Robert A Kloner

Affiliations: + Expand

Abstract

In many forms of erectile dysfunction (ED), cardiovascular risk factors, in particular arterial hypertension, seem to be extremely common. While causes for ED are related to a broad spectrum of diseases, a generalized vascular process seems to be the underlying mechanism in many patients, which in a large portion of clinical cases involves endothelial dysfunction, ie, inadequate vasodilation in response to endothelium-dependent stimuli, both in the systemic vasculature and the penile arteries. Due to this close association of cardiovascular disease and ED, patients with ED should be evaluated as to whether they may suffer from cardiovascular risk factors including hypertension, cardiovascular disease or silent myocardial ischemia. On the other hand, cardiovascular patients, seeking treatment of ED, must be evaluated in order to decide whether treatment of ED or sexual activity can be recommended without significantly increased cardiac risk. The guideline from the first and second Princeton Consensus Conference may be applied in this context. While consequent treatment of cardiovascular risk factors should be accomplished in these patients, many antihypertensive drugs may worsen sexual function as a drug specific side-effect. Importantly, effective treatment for arterial hypertension should not be discontinued as hypertension itself may contribute to altered sexual functioning; to the contrary, alternative antihypertensive regimes should be administered with individually tailored drug regimes with minimal side-effects on sexual function. When phosphodiesterase-5 inhibitors, such as sildenafil, tadalafil and vardenafil, are prescribed to hypertensive patients on antihypertensive drugs, these combinations of antihypertensive drugs and phosphodiesterase 5 are usually well tolerated, provided there is a baseline blood pressure of at least 90/60 mmHg. However, there are two exceptions: nitric oxide donors and alpha-adrenoceptor blockers. Any drug serving as a nitric oxide donor (nitrates) is absolutely contraindicated in combination with phosphodiesterase 5 inhibitors, due to significant, potentially life threatening hypotension. Also, a-adrenoceptor blockers, such as doxazosin, terazosin and tamsulosin, should only be combined with phosphodiesterase 5 inhibitors with special caution and close monitoring of blood pressure.

---

Chemical List

Adrenergic alpha-Antagonists|||Antihypertensive Agents|||Nitric Oxide Donors|||Phosphodiesterase Inhibitors|||3',5'-Cyclic-GMP Phosphodiesterases|||Cyclic Nucleotide Phosphodiesterases, Type 5|||PDE5A protein, human

---

Reference List

Auerbach S, Gittleman M, Mazzu A, et al. Simultaneous administration of vardenafil and tamsulosin does not induce clinically significant hypotension in patients with benign prostatic hyperplasia. Urology. 2004;64:998–1003.|||Bansal S. Sexual dysfunction in hypertensive men: a critical review of the literature. Hypertension. 1988;12:1–10.|||Benet AE, Melman A. The epidemiology of erectile dysfunction. Urol Clin North Am. 1995;22:699–709.|||Billups KL. Endothelial dysfunction as a common link between erectile dysfunction and cardiovascular disease. Current Sexual Health Reports. 2004;1:137–41.|||Blumentals WA, Gomez-Caminero A, Joo S, et al. Should erectile dysfunction be considered as a marker for acute myocardial infarction? Results from a retrospective cohort study. Int J Impot Res. 2004;16:350–3.|||Bohlen JG, Held JP, Sanderson MO, et al. Heart rate, rate-pressure product and oxygen uptake during four sexual activities. Arch Intern Med. 1984;14:1745–8.|||Brock GB, et al. Drug-induced male sexual dysfunction. An update. Drug Saf. 1993;8:414–26.|||Brock H, McMahon CG, Chen KK, et al. Efficacy and safety of tadalafil for the treatment of erectile dysfunction: results of integrated analyses. J Urol. 2002;168:1332–6.|||Bruckert E, Giral P, Heshmati HM, et al. Men treated with hypolipidaemic drugs complain more frequently of erectile dysfunction. J Clin Pharm Ther. 1996;21:89–94.|||Carvajal A, Lerida MT, Sanchez A, et al. ACE inhibitors and impotence: a case series from Spanish drug monitoring system. Drug Saf. 1995;13:130–1.|||Cardillo C, Kilcoyne CM, Quyyumi AA, et al. A selective defect in nitric oxide synthesis may explain the impaired endothelium-dependent vasodilation in patients with essential hypertension. Circulation. 1998;97:851–6.|||Cheitlin MD, Hutter AM, Brindis RG, et al. ACC/AHA Expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. J Am Coll Cardiol. 1999;33:273–82.|||Corbin JD. Pharmacology of phosphodiesterase-5 inhibitors. Int J Clin Prct. 2002;56:453–9.|||DeBusk RF. Sexual activity triggering myocardial infarction: one less thing to worry about. JAMA. 1996;275:1447–8.|||DeBusk R, Drory Y, Goldstein I, et al. Management of sexual dysfunction in patients with cardiovascular disease: recommendations of the Princeton Consensus Panel. Am J Cardiol. 2000;86:175–81.|||DeBusk RF. Evaluating the cardiovascular tolerance to sex. Am J Cardiol. 2000;86(suppl):51F–56F.|||Derby CA, Mohr BA, Goldstein I, et al. Modifiable risk factors and erectile dysfunction: can lifestyle changes modify risk? Urology. 2000;56:302–6.|||Dusing R. Effect of the angiotensin II antagonist valsartan on sexual function in hypertensive men. Blood Press Suppl. 2003;2:29–34.|||Emmick JT, Stuewe SR, Mitchell M. Overview of the cardiovascular effects of tadalafil. Eur Heart J. 2002;4:H32–H47.|||Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urol. 1994;151:54–61.|||Ferrario CM, Levy P. Sexual function in patients with hypertension: implications for therapy. J Clin Hyper tens. 2002;4:424–432.|||Gazzaruso C, Giordanetti S, De Amici E, et al. Relationship between erectile dysfunction and silent myocardial ischemia in apparently uncomplicated type 2 diabetes patients. Circulation. 2004;110:22–6.|||Greiner KA, Weigel JW. Erectile dysfunction. Am Fam Physician. 1996;54:1675–82.|||Gresser U, Gleiter CH. Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil. Review of the literature. Eur J Med Res. 2002;7:435–46.|||Gross GJ. Sildenafil and endothelial dysfunction in humans. Circulation. 2005;111:721–3.|||Hale TM, Okabe H, Heaton JP, et al. Antihypertensive drugs induce structural remodeling of penile vasculature. J Urol. 2001;166:739–45.|||Jackson G. Stable angina: drugs, angioplasty or surgery? Eur Heart J. 1997;18:B2–B10.|||Jackson G. Erectile dysfunction and cardiovascular disease. Int J Clin Pract. 1999;53:363–8.|||Jackson G. Sexual intercourse and stable angina pectoris. Am J Cardiol. 2000;86(suppl):35F–37F.|||Johannes CB, Araujo AB, Feldman HA, et al. Incidence of erectile dysfunction in men 40 to 69 years old: longitudinal results from the Massachusetts Male Aging Study. J Urol. 2000;163:460–3.|||Kaiser DR, Billups K, Mason C, et al. Impaired brachial artery endothelium-dependent and -independent vasodilation in men with erectile dysfunction and no other clinical cardiovascular disease. J Am Coll Cardiol. 2004;43:179–84.|||Keene LC, Davies PH. Drug-related erectile dysfunction. Adverse Drug React Toxicol Rev. 1999;18:5–24.|||Kim SW, Paick J, Park DW. Potential predictors of asymptomatic ischemic heart disease in patients with vasculogenic erectile dysfunction. Urology. 2001;58:441–5.|||Kloner RA, Jarow JP. Erectile dysfunction and sildenafil citrate and cardiologists. Am J Cardiol. 1999;83:576–82.|||Kloner RA. Hypertension as a risk for erectile dysfunction: implications for sildenafil use. J Clin Hypertens. 2000;2:33–6.|||Kloner RA, Brown M, Prisant LM, et al. Effect of sildenafil in patients with erectile dysfunction taking antihypertensive therapy. Am J Hypertens. 2001;14:515–24.|||Kloner RA. Erectile dysfunction and atherosclerosis. Curr Atheroscler Rep. 2002;4:397–401.|||Kloner RA, Hutter AH, Emmick JT, et al. Time course of the interaction between tadalafil and nitrates. J Am Coll Cardiol. 2003a;42:1855–60.|||Kloner RA, Mitchell M, Emmick JT. Cardiovascular effects of tadalafil in patients on common antihypertensive therapies. Am J Cardiol. 2003b;92:47M–57M.|||Kloner RA, Mohan P, Norenberg C, et al. Cardiovascular safety of vardenafil, a potent, highly selective PDE-5 inhibitor in patients with erectile dysfunction: an analysis of five placebo controlled trials. Pharmacol Ther. 2002;22:1371–6.|||Kloner RA. Cardiovascular effects of 3 phosphodiesterase-5 inhibitors approved for the treatment of erectile dysfunction. Circulation. 2004;110:3149–55.|||Kloner RA, Jackson G, Emmick JT, et al. Interaction between the phosphodiesterase 5 inhibitor, tadalafil, and the two α-blockers doxazosin and tamsulosin in healthy normotensive men. J Urol. 2004;172:1935–40.|||Kostis JB, Jackson G, Rosen R, et al. Sexual dysfunction and cardiac risk (the second Princeton Consensus Conference) Am J Cardiol. 2005;96:313–21.|||Langford HG, Rockfold RW, Wassertheil-Smoller S, et al. Effect of weight loss on thiazide produced erectile problems in men. Trans Am CLin Climatol Assoc. 1989;101:190–4.|||Levine LA. Diagnosis and treatment of erectile dysfunction. Am J Med. 2000;109:3S–12S.|||Llisterri JL, Lozano Vidal JV, Aznar Vicente J, et al. Sexual dysfunction in hypertensive patients treated with lorsatan. Am J Med Sci. 2001;321:336–41.|||Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med. 1986;315:1046–1051.|||MacMahon S, Petro R, Cutler J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–74.|||McVary KT, Carrier S, Wessells H, et al. Smoking and erectile dysfunction: evidence based analysis. J Urol. 2001;166:1624–32.|||Moulik PK, et al. Hypertension, anti-hypertensive drug therapy and erectile dysfunction in diabetes. Diabet Med. 2003;20:290–3.|||Muller JE, Mittleman MA, Maclure M, et al. Triggering myocardial infarction by sexual activity. JAMA. 1996;275:1405–9.|||Muller JE, Kaufmann PG, Luepker RV, et al. Mechanisms precipitating acute cardiac events. Review and recommendations of an NHLBI Workshop. Circulation. 1997;96:3233–9.|||Nabel EG, Ganz P, Gordon JB, et al. Dilation of normal and constriction of atherosclerotic coronary arteries caused by cold pressure test. Circulation. 1988;77:43–52.|||Nava E, Luscher TF. Endothelium-derived vasoactive factors in hypertension: nitric oxide and endothelin. J Hypertens. 1995;13(suppl 2):S39–S48.|||Nichols DJ, Muirhead GJ, Harness JA, et al. Pharmacokinetics of sildenafil after single oral doses in healthy male subjects: absolute bioavailability, food effects and dose proportionality. Br J Pharmacol. 2002;53:5S–12S.|||Nicolosi A, et al. Epidemiology of erectile dysfunction in four countries: cross-national study of the prevalence and correlates of erectile dysfunction. Urology. 2003;61:201–6.|||NIH Consensus Development Panel on Impotence. Impotence. JAMA. 1993;270:83–90.|||Nurnberg HG, et al. Treatment of antidepressant-associated sexual dysfunction with sildenafil: a randomized controlled trial. JAMA. 2003;289:56–64.|||Nusbaum MR. Erectile dysfunction: prevalence, etiology, and major risk factors. J Am Osteopath Assoc. 2002;102:S1–S6.|||Park K, Shin JW, Oh JK, et al. Restoration of erectile capacity in normotensive aged rats by modulation of angiotensin receptor type 1. J Androl. 2005;26:123–128.|||Pomara G, Morelli G, Pomara S, et al. Cardiovascular parameter changes in patients with erectile dysfunction using PDE-5 inhibitors: a study with sildenafil and vardenafil. J Androl. 2004;25:625–9.|||Ralph D, McNicholas T. UK management guidelines for erectile dysfunction. BMJ. 2000;321:499–502.|||Reffelmann T, Kloner RA. Therapeutic potential of phosphodiesterase 5 inhibitors for cardiovascular disease. Circulation. 2003;108:239–44.|||Reffelmann T, Kloner RA. Erectile dysfunction. Assessing risk and managing the cardiac patient. In: Broderick GA, editor. Oral pharmacotherapy for male sexual dysfunction. A guide to clinical management. Totowa, New Jersey: Humana Press Inc.; 2005a. pp. 199–220.|||Reffelmann T, Kloner RA. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety. Expert Opin Drug Saf. 2005b;4:531–40.|||Rizvi K, Hampson JP, Harvey JN. Do lipid-lowering drugs cause erectile dysfunction? A systemativ review. Fam Pract. 2002;19:95–8.|||Romeo JH, Seftel AD, Madhum ZT, et al. Sexual function in men with diabetes type 2: association with glycemic control. J Urol. 2000;166:739–45.|||Roth A, et al. Prevalence and risk factors for erectile dysfunction in men with diabetes, hypertension, or both diseases: a community survey among 1,412 Israeli men. Clin Cardiol. 2003;26:25–30.|||Schachter M. Erectile dysfunction and lipid disorders. Curr Med Res Opin. 2000;16:S9–S12.|||Schwarz ER, Rodriguez J. Sex and the heart. Int J Impot Res. 2005;17(Suppl 1):S4–6.|||Sairam K, Kulinskaya E, Boustead GB, et al. Prevalence of undiagnosed diabetes mellitus in male erectile dysfunction. BJU Int. 2001;88:68–71.|||Solomon H, Man J, Wierzbicki AS, et al. Erectile dysfunction: cardiovascular risk and the role of the cardiologist. Int J Clin Pract. 2003;57:96–9.|||Stein RA. The effect of exercise training on heart rate during sexual activity in the post-myocardial infarction patient. Circulation. 1977;55:738–40.|||Stern S. Symptoms other than chest pain may be important in the diagnosis of “silent ischemia” or “the sound of silence”. Circulation. 2005;111:e435–e437.|||Taddei S, Virdis A, Mattei P, et al. Vasodilation to acetylcholine in primary and secondary forms of hypertension. Hypertension. 1993;21:929–33.|||Tobbli JE, Stella I, Mazza ON, et al. Different effect of losartan and amlodipine on penile structures in male spontaneously hypertensive rats. Am J Nephrol. 2004;24:614–623.|||Thompson IM, Tangen CM, Goodman PJ, et al. Erectile dysfunction and subsequent cardiovascular disease. JAMA. 2005;294:2996–3002.|||Ueno M. The so-called coition death. Jpn J Leg Med. 1963;17:330–335.|||Vardi Y, Klerin L, Nassar S, et al. Effects of sildenafil citrate (Viagra) on blood pressure in normotensive and hypertensive men. Urology. 2002;59:747–52.|||Walczak MK, Lokhandwala N, Hodge MB, et al. Prevalence of cardiovascular risk factors in erectile dysfunction. J Gend Specif Med. 2002;6:19–21.|||Wallis RM, Corbin JD, Francis SH, et al. Tissue distribution of phosphodiesterase families and the effect of sildenafil on tissue cyclic nucleotides, platelet function and contractile responses of trabeculae carneae and aortic rings. Am J Cardiol. 1999;83:3C–12C.|||Webb DJ, Freedstone S, Allen MJ, et al. Sildenafil citrate and blood-pressure lowering drugs: results of drug interaction studies with an organic nitrate and a calcium channel antagonist. Am J Cardiol. 1999;83:21C–28C.|||Wysowski DK, Farinas E, Swartz L. Comparison of reported and expected deaths in sildenafil (Viagra) users. Am J Cardiol. 2002;89:1331–4.|||Zusman RM, Morales A, Glaser DB, et al. Overall cardiovascular profile of sildenafil citrate. Am J Cardiol. 1999;83:35C–44C.